Parabilis (NASDAQ: PBLS) reports RA Capital-linked grant of 20,215 stock options
Rhea-AI Filing Summary
Parabilis Medicines, Inc. reported that RA Capital–affiliated reporting persons filed a Form 4 for a compensation-related stock option grant linked to its common stock. The derivative award covers 20,215 shares of common stock at an exercise price of $20.00 per share and was granted at no cost.
The option vests in full on the earlier of June 9, 2027 or the date of Parabilis’ next annual stockholder meeting, subject to Dr. Simson’s continued service on that vesting date, and expires on June 8, 2036. Footnotes explain that under Dr. Simson’s arrangement with RA Capital’s investment adviser, the option is held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P., and net proceeds from any exercise will offset advisory fees, with all reporting persons disclaiming beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M.
Role
Director | Director | Director | Director | Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,215 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,215 shares (Indirect, See footnotes)
Footnotes (3)
- F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to Dr. Simson's continued service on such vesting date.
- F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F3. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Key Figures
Option grant size: 20,215 shares
Exercise price: $20.00 per share
Grant price: $0.00
+3 more
6 metrics
Option grant size
20,215 shares
Stock Option (Right to Buy) underlying common stock
Exercise price
$20.00 per share
Conversion or exercise price of stock option
Grant price
$0.00
Transaction price per option share at award
Post-grant derivative holdings
20,215 options
Total derivative securities following transaction
Vesting date trigger
June 9, 2027
Earlier of this date or next annual meeting for full vesting
Expiration date
June 8, 2036
Stock option expiration date
Key Terms
Stock Option (Right to Buy), exercise price, vest and become exercisable, beneficial ownership, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 20.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"shares underlying this option shall vest and become exercisable in full"
beneficial ownership financial
"disclaims beneficial ownership of any of the reported securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of its or his respective pecuniary interest therein"
advisory fees financial
"net cash or stock received upon exercise ... will offset advisory fees owed"
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did PBLS report for RA Capital on this Form 4?
Parabilis Medicines reported a Form 4 for an option grant covering 20,215 shares of common stock at a $20.00 exercise price. The grant is compensation-related, not an open-market trade, and is held for the benefit of RA Capital–managed funds.
What are the key terms of the Parabilis (PBLS) stock option grant?
The option covers 20,215 shares of Parabilis common stock with a $20.00 per share exercise price and no upfront cost. It expires June 8, 2036, providing a long-dated right to buy shares if vesting conditions are met.
When does the PBLS option granted in this Form 4 vest?
The option vests in full on the earlier of June 9, 2027 or the date of Parabilis’ next annual stockholder meeting. Vesting is conditioned on Dr. Simson continuing to serve through the relevant vesting date.
Who ultimately benefits from the Parabilis (PBLS) option reported by RA Capital?
Under Dr. Simson’s arrangement with RA Capital’s adviser, the option is held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P. Any net cash or stock from exercise offsets advisory fees owed to the adviser.
Do the RA Capital reporting persons claim beneficial ownership of the PBLS option?
The adviser, its general partner, the RA Capital funds, and Drs. Kolchinsky and Shah all disclaim beneficial ownership of the reported securities, except for any pecuniary interest. They also specifically disclaim beneficial ownership of the option and underlying common stock.
Is this PBLS Form 4 a buy or sell signal in the market?
This Form 4 reflects a grant or award of stock options, not an open-market purchase or sale. It records compensation-related derivative securities, so it is generally viewed as routine rather than a directional trading signal.